Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Non-Current Deferred Tax Liability (2019 - 2020)

Madrigal Pharmaceuticals (MDGL) has disclosed Non-Current Deferred Tax Liability for 2 consecutive years, with $14000.0 as the latest value for Q4 2020.

  • On a quarterly basis, Non-Current Deferred Tax Liability fell 77.42% to $14000.0 in Q4 2020 year-over-year; TTM through Dec 2020 was $14000.0, a 77.42% decrease, with the full-year FY2020 number at $14000.0, down 77.42% from a year prior.
  • Non-Current Deferred Tax Liability was $14000.0 for Q4 2020 at Madrigal Pharmaceuticals, down from $62000.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $62000.0 in Q4 2019 to a low of $14000.0 in Q4 2020.